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Nearly 841,000 people have died since 1999 from a drug overdose (CDC Wonder 2020).
The misuse of and addiction to opioids—including prescription pain relievers, heroin, and
synthetic opioids such as fentanyl—is a serious national crisis that affects public health as well as
social and economic welfare. By the time public health officials realized the dangers that came
with addiction to these drugs, an estimated 10.8 million people had misused prescription drugs
by 2018 alone (HHS 2020). It is with this startling statistic that since then the United States has
struggled to contain this crisis through various means. The most successful method of dealing
with the crisis is through public health programs called Medical Assisted Treatment (MAT),
which are provided through treatment centers across the United States. Considering the large
amount of funding that is being spent on combating the crisis, especially seen with the recent $26
billion settlement with Johnson & Johnson and distributors McKesson, AmerisourceBergen, and
Cardinal Health, it is more important than ever to understand and gauge the effectiveness of
these programs done through treatment centers and see if funding is being spent in the right
places. That is what I work towards with my research, seeing how best to put state and federal
funding into combating the opioid crisis.
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Background
The opioid crisis is a multifaceted issue that affects millions of people in the United
States and continues to grow at an alarming rate. An opioid can be any type of drug that
circulates in licit or illicit markets like prescription drugs, synthetic opiates or heroin. There has
been a significant amount of evidence that the origins of the crisis can be placed in the
introduction and marketing of Oxycontin during the late 1990’s, and the lack of regulation in the
healthcare industry that led to an massive increase in the availability of these drugs in the public
sector (Alpert et al. 2019, Vadivelu et al. 2018). The result of this is that between 1999 and 2010,
opioid prescriptions increased by 300% (Kunins et al., 2013). Over this time period the increase
in mortality rates has taken a significant toll on the United States, from 2000 to 2014 nearly half
a million persons in the United States have died from drug overdoses (Rudd et al. 2016). The
number of deaths each year had been steadily rising since the 1990’s up until 2018, in which the
death rate dropped to 68,557 from 2017’s 70,237 (Goodnough, Katz, and Sanger-Katz 2019).
This graph pulls from respective state data on mortality rates, and portrays quite clearly the toll
this crisis has placed on American lives
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Note: Using the data from Drug Overdose Mortality by State 2021
(https://www.cdc.gov/nchs/pressroom/sosmap/drug_poisoning_mortality/drug_poisoning.htm),
As far as treatment for those suffering from opioid addiction, there have been a few
consistent methods that have been utilized to get people back on track. Along with utilizing
Naloxone to revitalize an overdosed person in an emergency scenario, another useful combative
tool is what’s called Medical-Assisted-Treatment programs (MAT) which use medication along
with counseling to solve addiction problems (Pitt, Humphreys, and Brandeau 2018). Both of
these methods are utilized in situations in which an opioid user is combating their addiction, one
preemptive tool that tries to slow the opioid trade is what is called Prescription Drug Monitoring
Programs. These are state-run electronic databases used to track the prescribing and dispensing
of controlled prescription drugs to patients (“National Threat Assessment” 2017). They are
designed to monitor this information for suspected CPD abuse or diversion, and emerging
evidence has shown that PDMP’s are effective at significantly lowering opioid misuse in broad
application on state levels (Buchmueller and Carey, n.d.). It is because of the magnitude of total
deaths so far and the continued misuse of opioids that so many researchers have placed a great
deal of study into this issue. In order to reduce future morbidity and mortality rates, a systemic
look at how federal and state funding is being utilized to combat the opioid crisis needs to be
taken into consideration.
In order to find out this multifaceted question surrounding federal and state funding
towards the opioid crisis, I started first with finding what previous budgetary plans had been put
out over the years. This was provided from organizations like the National Institute of Drug
Abuse that specifically detailed what funding from the national government would be spent
towards with respect to programs and treatment on the federal level. Coupled with the recent
news of the $26 Billion settlement which will be finalized in September, finding out where
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federal funding was being allocated was not as difficult a task as I initially thought. One aspect
of my research that I still needed to look at was the state level of funding for the opioid crisis,
which would be harder to find information on as each state has a different way of reporting
where funding is being spent on combating the opioid crisis. I found databases that individual
states did as part of their private research, such as with Indiana and the county level aggregate
cost equation that researchers from the University of Indiana created (Brewer and Freeman,
2018). Through extensive research I found an aspect of state funding that directly correlates with
the usage of treatment programs in the states, and that was the access to medicaid which appears
in datasets for those admitted to treatment centers. It was from this point that my topic came
through with the dataset I found, and will be expanded upon later in this paper.
Literature Review/Federal and State Funding
This crisis requires a systematic analysis of how federal and state funding is being
allocated to properly solve it. My research adds to an already existing literature of scholarly
articles that analyzes the impact of federal and state funding on the overall crisis. The question
that these researchers look at is how best to measure the economic burden that combating the
opioid crisis brings about (Florence et al. 2016). Emerging studies have charted different
methods to accomplishing this task, with a great deal focusing on how aggregate costs are
accumulated in states. One example from the Indiana Business Review allocates damages to
counties in Indiana through direct costs (first response, long-term treatment), indirect costs
through lost GSP in labor markets, and present value of all lost future productivity of past
opioid-related casualties (Brewer and Freeman, n.d.). Different researchers have looked at
datasets that all contribute to a greater narrative, such as the CDC mortality data and the National
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Vital Statistics System for opioid overdoses and deaths (Hollingsworth, Ruhm, and Simon 2017,
Florence et al. 2016). Analysis stems from strategies for how opioid funding can be best used in
specific treatment programs, and the findings that they attain are best recommended strategies
such as increasing opioid grant funding on state targeted response (STR) programs (High et al.
2019). The findings that different researchers have found all look at case examples of states that
have been the most effective at reducing opioid deaths, such as with Vermont which actually
expanded Medicaid before the ACA officially took effect, and about 80 percent of patients in
medication-assisted treatment in the state are covered by Medicaid (Knopf 2017).
Data
When taking a look at how researchers have gathered data to provide analysis on the
opioid crisis, it is important to consider both what databases they have pulled from and how they
adjusted their variables to make their own conclusions about the topic. There are a great deal of
datasets available that can be utilized in unique ways that fall under the topic of the opioid crisis
and it can be challenging to find which one suits a specific research question. One of the largest
publicly available websites that hosts databases that feature opioid statistics are the ones
provided by the Substance Abuse and Mental Health Data Archive (SAMHDA). The multitude
of datasets provided surrounding the overall drug abuse topic gives researchers the option to
create a wide range of analysis through regressions and data tables on the crisis over the years. A
few cases examples will be looked at using one dataset from SAMHDA, the Treatment Episode
Data Set-Admissions (TEDS-A), which reports characteristics of clients admitted to specialty
substance use treatment programs licensed or funded by public agencies in U.S. states,
Washington, DC and Puerto Rico (Batts et al. 2016).
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The TEDS-A dataset provides demographic, clinical, and substance use characteristics of
admissions to alcohol or drug treatment in facilities that report to state administrative data
systems (SAMHDA 2018). Through these systems states send data that includes general
demographic information, primary along with secondary and tertiary substances upon admission,
source of referral for treatment, record of previous treatment episodes and whether or not
medication assisted therapy (MAT) programs were utilized. This specific dataset covers only the
year of 2018, with 1,935,541 different cases of people being admitted to substance abuse
treatment that year. This dataset is ideal for my research as it provides the greatest amount of
variables surrounding the tracking method for the amount of people in each state who were
admitted to substance abuse treatment, and the versatile dataset will prove useful in forming my
research on state and federal funding onto the total admissions in each state.
Literature Surrounding Dataset
This TEDS-A dataset has a wide range of variables that allows researchers to emphasize
their specific points, and trends among these papers with respect to the data will now be looked
at. One of the most prevalent trends in grouping how this data will be used with respect to the
crisis is to look at the different categories of opioid users that have entered these substance use
treatment programs. One paper that utilizes this as their main point titled Medications for opioid
use disorder among American Indians and Alaska natives: Availability and use across a national
sample looks at the access that American Indians and Alaskan natives have to medications used
to treat opioid disorders. The way that this source uses the TEDS-A dataset is by cross
referencing it with another dataset from SAMHDA called National Survey of Substance Abuse
Treatment Services (N-SSATS), which is an annual census of characteristics of public and
private substance use treatment facilities in the U.S., including information on types of
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medications offered (Batts et al. 2016). Using these two datasets, the researchers looked at the
availability of medication for opioid use disorder in facilities through the N-SSATS dataset and
the client level through the TEDS-A dataset among American Indian and Alaskan natives
(Krawczyk et al. 2021). With this the researchers conducted multivariate regression analysis
among different race groups to see the access the American Indian and Alaskan natives had to
these medications when compared to other groups. This form of data collection shows the
importance of picking a specific topic and honing in on how it will answer the research question,
and will be important to consider for what I will add with my research.
Another article that does a similar form of data analysis is Medicaid Expansion Increased
Medications For Opioid Use Disorder Among Adults Referred By Criminal Justice Agencies, the
main difference being that the researchers pulled TEDS-A datasets from the past ten years. The
main independent variables are the sources of treatment referral, and was grouped by criminal
justice referrals and noncriminal/justice referrals which makes sense as the researchers want to
chart the availability of opioid use disorder medication before and after Medicaid. To reinforce
this the main dependent variable are the receipts of medication for opioid use disorder, and
assessed age, race/ethnicity, employment status, sex, educational attainment, service setting, and
region by referral source (Khatri, Howell, and Winkelman 2021). This study would also stratify
their regression analysis in a similar manner to the previous article, with race/ethnicity being the
largest group to do this. One limitation of the TEDS-A dataset is because the unit of analysis
within TEDS-A is a treatment admission, not an individual; some individuals may be represented
more than once (Khatri, Howell, and Winkelman 2021). The way that this article looks at data
over time will be important to consider going forward with my research.
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Another article that utilizes this dataset is The role of health insurance on treatment for
opioid use disorders: Evidence from the Affordable Care Act Medicaid expansion, which
analyzes the utility of the Medicaid act in treating opioid use disorder. This source uses general
administrative data including TEDS-A from 2007 to 2016, specifically looking at how Medicaid
coverage of opioid use disorder treatment has increased from this time period. To look at how
health care coverage has changed over this time, control variables are pain clinic laws and PDMP
to see how supply reduction has changed over time. One limitation of the TEDS-A dataset as
mentioned in this article is the lack of information from certain years as it is a supplemental
dataset, and missing values throughout the dataset (Meinhofer and Witman 2018). Taking this
dataset and applying it to the implementation of public policy is an aspect of econometric
research that relates heavily to my research question, and understanding how I can do that for
when my dataset will be important.
An article that takes a look at the TEDS-A dataset in a new comparative manner is
Disparities in Opioid Use Disorder Treatment Admissions in the United States. The way that this
dataset was used was by identifying the group of individuals who have received treatment for
opioid use disorder and comparing the changes between the city of Cincinnati and other major
cities. Logistic regression models were performed to assess the differences for treatment wait
time and type of planned treatment. From this three different models were created that showed
the covariates of the outcomes (Mallow, Mercado, and Topmiller 2020). Similarly to the previous
article, one of the limitations of this dataset is the fact that the information provided is dependent
on the public fund, and as such some states are missing information and it is all self-reported
information. It is important to consider the limitations of the dataset, so when I utilize it I will be
cognizant of the weaknesses and give proper analysis of why these limitations exist.
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Description of Data
Of all the variables present in the TEDS-A dataset, the dependent variable I consider for
analysis is METHUSE. This variable identifies whether or not a patient who had been admitted
to a treatment facility used opioid medications such as methadone, buprenorphine, and/or
naltrexone (SAMHDA 2018). Of the 1,935,541 admission cases, 296,778 were marked as having
utilized opioid medications. I include a set of independent variables that define the usage of
opioid medications and the relationship it has with co-existing mental and substance use
disorders; individual (patients) characteristics capturing race, ethnicity, income, employment,
education and marital status, and types of health insurance. The information in the datasets has
breakdowns based on the US census divisions and regions which I hope to observe differential
effects of both state and federal fundings across divisions.
Many variables in this dataset have missing observations for unknown reasons and they
take a value of 9 which I don’t include in the dataset for analysis. Along with this, one of the
independent variables that indicates if any client had any co-existing mental and substance use
disorders (PSYPROB) was modified to a binary variable. If they have none the PSYPROB
variable takes the value of 0. I created a number of binary variables for variables of interest to
use for the regression analysis.
These independent variables, which can also be called predictor variables as they are all
being put in comparison to one dependent variable, will be utilized to show some form of
numerical change that is focused on METHUSE and is different for each variable. The total
number of observations varies for almost all variables as some are missing. MARSTAT and
EDUC are variables to control for marital status and education level of individuals. I use these
variables to define, as they are grouped by different sections that will allow for direct comparison
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between these values and those who were not married or had no education.  After I had
eliminated the invalid numbers from each of the variables in this dataset, I set about making new
binary variables from all the different independent variables that will be utilized to dig deeper
into specific key groups that respond higher to METHUSE than if we just left the dataset as is.
Certain modifications that I made to these variables were done for the sake of better aggregating
the grouping of values, such as with the AGE variable. I changed how it was grouped in the
dataset from having values 1-12 be every 4 years of age to groups of teenagers (12-21) and then
ten year gaps in each binary variable. This is one example of the choices I made to this dataset,
and other modifications I created were done in a similar vein as this in that I chose to create
better clarification for specific groups that will impact METHUSE. All the new variables that I
will be using for my regression analysis are in the table below, the values for the mean add up to
1.0 as they each are binary and are in direct correlation with one another and a variable in the
original dataset.
Table 1: Descriptive Statistics for Original Dataset




SELFPAYINS 854,133 0.065231 0.2469333 0 1
PRIVATEINS 854,133 0.05065 0.2192825 0 1
MEDICARE 854,133 0.020473 0.1416131 0 1
MEDICAID 854,133 0.566507 0.4955574 0 1
GOVPAYMENTS 854,133 0.226327 0.4184532 0 1
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NOCHARGE 854,133 0.02348 0.1514222 0 1
OTHERPRIMPAY 854,133 0.047332 0.2123486 0 1
Type of Health
Insurance:
PRIVATEINS 951,904 0.077166 0.2668554 0 1
MEDICAID 951,904 0.555035 0.4969622 0 1
MEDICARE 951,904 0.077442 0.267291 0 1
NOHLTHINS 951,904 0.290357 0.4539273 0 1
Division:
USTERRITOR~S 1,935,541 0.001524 0.0390036 0 1
NEW ENGLAND 1,935,541 0.093026 0.2904685 0 1
MIDDLE ATLANTIC 1,935,541 0.20393 0.4029177 0 1
ESTNRTHCENTRAL 1,935,541 0.115516 0.3196431 0 1
WSTNRTHCENTRAL 1,935,541 0.086795 0.2815343 0 1
SOUTH ATLANTIC 1,935,541 0.195571 0.3966394 0 1
ESTSTHCENTRAL 1,935,541 0.034075 0.1814212 0 1
WSTSTHCENTRAL 1,935,541 0.041478 0.1993938 0 1
MOUNTAIN 1,935,541 0.142166 0.3492203 0 1
PACIFIC 1,935,541 0.085921 0.280247 0 1
Race:
ALASKA NATIVE 1,859,620 0.001928 0.0438645 0 1
AMERICAN IN~N 1,859,620 0.026955 0.1619519 0 1
BLACK 1,859,620 0.195004 0.3962042 0 1
WHITE 1,859,620 0.673462 0.4689466 0 1
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PACIFICISL~R 1,859,620 0.000123 0.0110721 0 1
ASIAN 1,859,620 0.006156 0.0782155 0 1
OTHERSINGL~E 1,859,620 0.072204 0.2588246 0 1
TWOORMORER~S 1,859,620 0.020466 0.1415862 0 1
NATIVEHAWA~N 1,859,620 0.003703 0.0607432 0 1
Ethnic:
PUERTORICAN 1,856,174 0.035981 0.1862415 0 1
MEXICAN 1,856,174 0.037171 0.1891809 0 1
CUBAN 1,856,174 0.034306 0.1820142 0 1
NOT HISPANIC 1,856,174 0.861648 0.3452695 0 1
GENERAL HIS~C 1,856,174 0.030895 0.1730326 0 1
Marital Status:
NEVER MARRIED 1,508,148 0.677985 0.4672488 0 1
MARRIED 1,508,148 0.125797 0.3316209 0 1
SEPERATED 1,508,148 0.055477 0.2289096 0 1
DIVORCED/WIDOW
ED
1,508,148 0.14074 0.3477534 0 1
Education:
BELOW GRADE8 1,716,995 0.058012 0.233767 0 1
GRADES 9-11 1,716,995 0.211143 0.40812 0 1
GRADE12 OR GED 1,716,995 0.481402 0.4996541 0 1
COLLEGEUPT~S 1,716,995 0.183211 0.3868398 0 1
COLLEGEGRA~E 1,716,995 0.066231 0.2486862 0 1
Employment:
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FULL TIME 1,709,433 0.184812 0.3881452 0 1
PART TIME 1,709,433 0.07261 0.2594954 0 1
UNEMPLOYED 1,709,433 0.372776 0.4835433 0 1
NOT IN LABOR
FORCE
1,709,433 0.369802 0.4827511 0 1
Source of Income:
WAGES 1,183,287 0.292067 0.4547131 0 1
PUBLICASSI~E 1,183,287 0.084999 0.2788801 0 1
RETIREMENT~Y 1,183,287 0.075372 0.2639912 0 1
OTHERPRIMINC 1,183,287 0.174006 0.3791148 0 1
NOPRIMINC 1,183,287 0.373556 0.483748 0 1
Age group:
AGE 12-20 1,935,541 0.060916 0.2391758 0 1
AGE 21-29 1,935,541 0.256324 0.436603 0 1
AGE 30-39 1,935,541 0.3084 0.4618326 0 1
AGE 40-49 1,935,541 0.18192 0.3857784 0 1
AGE 50 and older 1,935,541 0.192441 0.3942175 0 1
From this descriptive table, there are a few key variables that have noticeable details. By
looking at the mean values for these variables and identifying where large groups are present
narrative details surrounding who is admitted to these treatment facilities will come about. Two
of the most noticeable details are with the large number of admissions of people who were on
medicaid, seen in both the HLTHINS and PRIMPAY primary variables. Seen with both
MEDICAIDPRIMARYPAY and MEDICAIDHLTHINS, the mean values are a significant
percentage of the total amount (0.566507 = 56.6% for HLTHINS, 0.555035 = 55.5% for
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PRIMPAY). This is not something that I expected when looking at the descriptive statistics, and
considering that medicaid is a state and federal program focused on providing health coverage
for those with low income, the purpose of medicaid fits directly with my research topic and
provides me with the largest pool of data. Another stark percentage value that sticks out was the
racial distribution, with the largest percentage being white (0.673462 = 67.3%) which speaks to
what groups are most able to get into the proper treatment for their opioid use disorder. Another
high percentage are those who never married (0.677985 = 67.7%) and those who only graduated
from high school (0.481402 = 48.1%), these two percentages combined with the other high
percentages show the general grouping of a person that requires treatment at an admission
facility. The newly named created variables are shown in table 2 below, and a short description
of each one is shown along with it.
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Groupings of states that are





















Grades 9 to 11
Grade 12/GED





Not in Labor Force
Source of Primary Income:







Age group: Client’s age
Age 21 to 29
Age 30 to 39
Age 40 to 49
Age 50 to Older
Female
With all of this detail surrounding the variables, it was time to create a comparable format
that unites data with the narratives above. The way that this will be accomplished is by
showcasing histographic models comparing a modified race variable with the HLTHINS and
PRIMPAY variables. The new race variable that was created groups the total races in the dataset
from 9 groups to just 4, this is done in order to better compare in a histogram. The four racial
groups in the race2 variable are white, black, asian, and other racial groups which are the 4
numbers in the titles of each smaller graph. The 4 groups of HLTHINS are having private
insurance, medicaid and medicare, and no health insurance available.
19
The biggest conclusion from this graph is that white (1) and black (2) groups have the
highest frequency for getting access to health insurance and the largest group is the medicaid (2)
and no health insurance (4). The implication that white people have the most readily available
access to health insurance, specifically one that is backed up by federal and state funding is an
interesting spin on my research topic.
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Similarly with the HLTHINS histogram, predominantly white and black groups have the
highest association with medicaid as a source of payment for entering these treatment facilities.
One of the main interesting facts about this graph is the other government payments section,
which is surprisingly the second highest percentage for both white and black groups and the
other race groups. Looking at these different racial groups in isolation from the others would be
necessary to better understand how these groups relate to other key variables, which will be
accomplished through running a probit regression analysis with one of these racial groups being
the control variable by being excluded from the regression.
Method of Analysis
I chose the probit model for estimation as the independent variable METHUSE is a
binary variable. The probit function is able to create a nonlinear relationship from the binary
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variable, and is thus able to be properly used in this dataset. In order to properly represent this
dataset, a variety of new variables had to be created that broke up the different categorical
variables into separate binary variables. This allows for greater look at specialized factors in
different areas, such as looking at each of the different racial groups individually and how they
each relate to the dependent variable. From these variables, a final regression model utilizing the
probit function was created, all variables are modeled with the use of medication assisted
therapy.
Table 3: Probit estimates of relationship between use of medication assisted therapy and
variables of admitted patients
Variable Coefficient Standard Error
Reported Opiates 0.481513 0.006591***
Reported Methadone 0.672559 0.034965***
Mental/Substance Disorders 0.017739 0.004969***
Types of Health Insurance:
Medicaid Health Insurance 0.316267 0.010013***
Medicare Health Insurance 0.022816 0.01263
No Health Insurance -0.09308 0.010461***
Census Division:
New England 0.30657 0.041684***
Middle Atlantic 0.59608 0.041733***
East North Central -0.71771 0.043699***
West North Central -0.91948 0.042636***
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South Atlantic 0.213773 0.042026***
East South Central -0.42389 0.0427***






Other Race 0.121324 0.029148***
Marital Status:
Never Married 0.043552 0.011395***
Now Married 0.105531 0.012769***
Divorced/Widowed -0.04145 0.012603**
Education:
Grades 9 to 11 0.100116 0.010754***
Grade 12/GED 0.020665 0.00936*
College up to 3 Years -0.01365 0.010565
College Graduate -0.1256 0.012734***
Employment:
Full time -0.09102 0.010331***
Unemployed -0.07944 0.011603***
Not in Labor Force -0.16357 0.011655***
Primary Income:
Wages -0.27562 0.011543***
Public Assistance -0.08037 0.010364***
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Other Primary Income -0.22351 0.010037***
No Primary Income -0.31179 0.008718***
Age:
Age 21 to 29 0.615782 0.017135***
Age 30 to 39 0.750545 0.017066***
Age 40 to 49 0.718954 0.017589***
Age 50 to Older 0.745786 0.017851***
Female 0.185893 0.005127***
Constant Value -2.23847 0.060631***
Discussion of results
Several important factors that stick out in this regression analysis are the ones that relate
to what I discussed in the introduction section. Starting with the access a person had to medicaid
in a treatment center, there is a higher probability that person would actively utilize an MAT
program. The data shows a positive relationship with medicaid and MAT programs, with the
positive coefficient for medicaid health insurance leading to a numerical increase in MAT
programs (0.316267). Looking at the census divisions, it is interesting to see the positive relation
that New England (Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and
Vermont) Middle Atlantic (New Jersey, New York, and Pennsylvania) and South Atlantic
(Delaware, District of Columbia, Florida, Georgia, Maryland, North Carolina, South Carolina,
Virginia, and West Virginia). These regions and the increased access to MAT programs as seen in
the dataset (0.30657, 0.59608, 0.213773) showcases what regions have greater percentage
access to these programs for people who need it as opposed to other regions. A case could be
made for these regions utilizing their funding more effectively than other regions of the United
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States. Looking at the race binary variables, considering both the previous histograms with the
conclusion that the white variable had the highest access to medicaid, it makes sense that the
white coefficient has the highest percentage for receiving access to MAT treatment (0.318489)
than the other races (0.054451 for black, 0.121324 for other races). These results suggest that
region along with racial identity decide whether or not a person gets access to proper treatment
for addiction through MAT programs, and this predictor is prevalent across other variables like
age and primary source of income. It seems that in order to allow for better treatment in the
United States, making sure that funding is provided to different regions than the ones discussed
here and allowing marginalized populations receive access to medicaid will lead to greater access
to treatment programs.
Conclusion
To sum up everything that has been brought up so far, funding meant for combating the
opioid crisis will need to make revisions that highlight disparities brought up in the data of this
research. Making sure that funding from the federal government is utilized with accountability
on the states is another important aspect that needs to be brought to the forefront even as funding
continues to be doled out to the states. The findings of this research allows for a greater look into
how discrepancies among different factors impact how people receive access to medical
treatment, and makes clear that the road for reforming the American healthcare field is an
important stepping stone to solving the opioid crisis.
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APPENDIX
List of variables used in analysis
Variable Obs Mean Std. Dev. Min Max
METHUSE 1,793,132 0.165508 0.3716387 0 1
METHFLG 1,935,541 0.003458 0.0587026 0 1
OPSYNFLG 1,935,541 0.122163 0.3274738 0 1
PSYPROB 1,620,475 0.411036 0.4920218 0 1
HLTHINS 951,904 2.580989 0.9891858 1 4
PRIMPAY 854,133 4.097816 1.243714 1 7
RACE 1,859,620 4.942947 1.002045 1 9
ETHNIC 1,856,174 3.814305 0.7093849 1 5
MARSTAT 1,508,148 1.658972 1.086335 1 4
EDUC 1,716,995 2.988506 0.944033 1 5
EMPLOY 1,709,433 2.927568 1.084627 1 4
PRIMINC 1,183,287 3.251985 1.690563 1 5
DETNLF 563,807 4.123024 1.170725 1 5
AGE 1,935,541 6.927559 2.445001 1 12
METHUSE= Whether the use of opioid medications such as methadone, buprenorphine, and/or
naltrexone is part of the client’s treatment plan.
METHFLG= Flag records if non-prescription methadone was reported as the primary, secondary,
or tertiary substance at the time of admission.
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OPSYNFLG= Flag records if other opiates or synthetics were reported as the primary, secondary,
or tertiary substance at the time of admission.
PSYPROB= Indicates whether the client has co-occurring mental and substance use disorders.
HLTHINS= This field specifies the client's health insurance at admission. The insurance may or
may not cover behavioral health treatment.
PRIMPAY= This field identifies the primary source of payment for this treatment episode
anticipated at the time of admission.
RACE= This field identifies the client’s race
ETHNIC= This field identifies the client’s ethnicity
MARSTAT= This field identifies the client’s marital status
EDUC= This field identifies the client’s education level
EMPLOY= This field identifies the client’s employment status
PRIMINC= This field identifies the client’s principal source of financial support
DETNLF= Provides more detailed information about those clients who are coded as '04 Not in
labor force' in Employment Status
AGE= This field identifies the client’s age
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